{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T10:55:20Z","timestamp":1785840920412,"version":"3.56.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1038\/s41409-026-02929-7","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:43:44Z","timestamp":1780533824000},"page":"1024-1032","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Non-gene-edited, CD19-targeted, allogeneic CAR-T cell therapy for relapsed or refractory B-cell acute lymphoblastic leukemia: an open-label, single-arm phase 1 study"],"prefix":"10.1038","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-3767-0071","authenticated-orcid":false,"given":"Chenxue","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2821-9376","authenticated-orcid":false,"given":"Lei","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0307-6203","authenticated-orcid":false,"given":"Miaomiao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4741-257X","authenticated-orcid":false,"given":"Sujun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6198-0829","authenticated-orcid":false,"given":"Qianwen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaichun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5594-0303","authenticated-orcid":false,"given":"Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5591-2168","authenticated-orcid":false,"given":"Xingbing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"key":"2929_CR1","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018;378:439\u201348.","journal-title":"N Engl J Med"},{"key":"2929_CR2","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/s41417-023-00593-3","volume":"30","author":"M Elsallab","year":"2023","unstructured":"Elsallab M, Ellithi M, Hempel S, Abdel-Azim H, Abou-El-Enein M. Long-term response to autologous anti-CD19 chimeric antigen receptor T cells in relapsed or refractory B cell acute lymphoblastic leukemia: a systematic review and meta-analysis. Cancer Gene Ther. 2023;30:845\u201354.","journal-title":"Cancer Gene Ther"},{"key":"2929_CR3","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1093\/oncolo\/oyac163","volume":"27","author":"N Bouchkouj","year":"2022","unstructured":"Bouchkouj N, Lin X, Wang X, Przepiorka D, Xu Z, Purohit-Sheth T, et al. FDA Approval Summary: Brexucabtagene Autoleucel for Treatment of Adults With Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia. Oncologist. 2022;27:892\u20139.","journal-title":"Oncologist"},{"key":"2929_CR4","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1158\/1078-0432.CCR-18-2035","volume":"25","author":"MC O\u2019Leary","year":"2019","unstructured":"O\u2019Leary MC, Lu X, Huang Y, Lin X, Mahmood I, Przepiorka D, et al. FDA Approval Summary: Tisagenlecleucel for Treatment of Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia. Clin Cancer Res. 2019;25:1142\u20136.","journal-title":"Clin Cancer Res"},{"key":"2929_CR5","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2406526","volume":"391","author":"C Roddie","year":"2024","unstructured":"Roddie C, Sandhu KS, Tholouli E, Logan AC, Shaughnessy P, Barba P, et al. Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia. N Engl J Med. 2024;391:2219\u201330.","journal-title":"N Engl J Med"},{"key":"2929_CR6","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1080\/1750743X.2024.2408048","volume":"16","author":"X Chen","year":"2024","unstructured":"Chen X, Gao Y, Zhang Y. Allogeneic CAR-T cells for cancer immunotherapy. Immunotherapy. 2024;16:1079\u201390.","journal-title":"Immunotherapy"},{"key":"2929_CR7","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","volume":"19","author":"S Depil","year":"2020","unstructured":"Depil S, Duchateau P, Grupp SA, Mufti G, Poirot L. Off-the-shelf\u2019 allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020;19:185\u201399.","journal-title":"Nat Rev Drug Discov"},{"key":"2929_CR8","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abq3010","volume":"14","author":"G Ottaviano","year":"2022","unstructured":"Ottaviano G, Georgiadis C, Gkazi SA, Syed F, Zhan H, Etuk A, et al. Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia. Sci Transl Med. 2022;14:eabq3010.","journal-title":"Sci Transl Med"},{"key":"2929_CR9","doi-asserted-by":"publisher","first-page":"3853","DOI":"10.1158\/0008-5472.CAN-14-3321","volume":"75","author":"L Poirot","year":"2015","unstructured":"Poirot L, Philip B, Schiffer-Mannioui C, Le Clerre D, Chion-Sotinel I, Derniame S, et al. Multiplex Genome-Edited T-cell Manufacturing Platform for \u201cOff-the-Shelf\u201d Adoptive T-cell Immunotherapies. Cancer Res. 2015;75:3853\u201364.","journal-title":"Cancer Res"},{"key":"2929_CR10","doi-asserted-by":"publisher","first-page":"e833","DOI":"10.1016\/S2352-3026(22)00245-9","volume":"9","author":"R Benjamin","year":"2022","unstructured":"Benjamin R, Jain N, Maus MV, Boissel N, Graham C, Jozwik A, et al. UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial. Lancet Haematol. 2022;9:e833\u2013e843.","journal-title":"Lancet Haematol"},{"key":"2929_CR11","volume":"33","author":"W Sun","year":"2022","unstructured":"Sun W, Jiang Z, Jiang W, Yang R. Universal chimeric antigen receptor T cell therapy - The future of cell therapy: A review providing clinical evidence. Cancer Treat Res Commun. 2022;33:100638.","journal-title":"Cancer Treat Res Commun"},{"key":"2929_CR12","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.bbmt.2018.09.024","volume":"25","author":"Z Mahmoudjafari","year":"2019","unstructured":"Mahmoudjafari Z, Hawks KG, Hsieh AA, Plesca D, Gatwood KS, Culos KA. American Society for Blood and Marrow Transplantation Pharmacy Special Interest Group Survey on Chimeric Antigen Receptor T Cell Therapy Administrative, Logistic, and Toxicity Management Practices in the United States. Biol Blood Marrow Transpl. 2019;25:26\u201333.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2929_CR13","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","volume":"22","author":"AC Harris","year":"2016","unstructured":"Harris AC, Young R, Devine S, Hogan WJ, Ayuk F, Bunworasate U, et al. International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium. Biol Blood Marrow Transpl. 2016;22:4\u201310.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2929_CR14","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.annonc.2020.10.478","volume":"32","author":"ML Schubert","year":"2021","unstructured":"Schubert ML, Schmitt M, Wang L, Ramos CA, Jordan K, M\u00fcller-Tidow C, et al. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Ann Oncol. 2021;32:34\u201348.","journal-title":"Ann Oncol"},{"key":"2929_CR15","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1200\/JCO.21.00917","volume":"39","author":"C Roddie","year":"2021","unstructured":"Roddie C, Dias J, O\u2019Reilly MA, Abbasian M, Cadinanos-Garai A, Vispute K, et al. Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia. J Clin Oncol. 2021;39:3352\u201363.","journal-title":"J Clin Oncol"},{"key":"2929_CR16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1182\/blood.2020009098","volume":"138","author":"BD Shah","year":"2021","unstructured":"Shah BD, Bishop MR, Oluwole OO, Logan AC, Baer MR, Donnellan WB, et al. KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed\/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. Blood. 2021;138:11\u201322.","journal-title":"Blood"},{"key":"2929_CR17","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","volume":"398","author":"BD Shah","year":"2021","unstructured":"Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021;398:491\u2013502.","journal-title":"Lancet"},{"key":"2929_CR18","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1016\/S0140-6736(20)32334-5","volume":"396","author":"R Benjamin","year":"2020","unstructured":"Benjamin R, Graham C, Yallop D, Jozwik A, Mirci-Danicar OC, Lucchini G, et al. Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies. Lancet. 2020;396:1885\u201394.","journal-title":"Lancet"},{"key":"2929_CR19","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1111\/bjh.17662","volume":"194","author":"MR Hines","year":"2021","unstructured":"Hines MR, Keenan C, Maron Alfaro G, Cheng C, Zhou Y, Sharma A, et al. Hemophagocytic lymphohistiocytosis-like toxicity (carHLH) after CD19-specific CAR T-cell therapy. Br J Haematol. 2021;194:701\u20137.","journal-title":"Br J Haematol"},{"key":"2929_CR20","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1038\/s41409-019-0487-3","volume":"54","author":"S Fried","year":"2019","unstructured":"Fried S, Avigdor A, Bielorai B, Meir A, Besser MJ, Schachter J, et al. Early and late hematologic toxicity following CD19 CAR-T cells. Bone Marrow Transpl. 2019;54:1643\u201350.","journal-title":"Bone Marrow Transpl"},{"key":"2929_CR21","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KMAK Cappell","year":"2023","unstructured":"Cappell KMAK, James N. Long-term outcomes following CAR T cell therapy: what we know so far. Nat Rev Clin Oncol. 2023;20:359\u201371.","journal-title":"Nat Rev Clin Oncol"},{"key":"2929_CR22","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1182\/blood.2023020621","volume":"143","author":"S Ghorashian","year":"2024","unstructured":"Ghorashian S, Lucchini G, Richardson R, Nguyen K, Terris C, Guvenel A, et al. CD19\/CD22 targeting with cotransduced CAR T cells to prevent antigen-negative relapse after CAR T-cell therapy for B-cell ALL. Blood. 2024;143:118\u201323.","journal-title":"Blood"},{"key":"2929_CR23","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1038\/s41375-021-01281-7","volume":"35","author":"ME Dourthe","year":"2021","unstructured":"Dourthe ME, Rabian F, Yakouben K, Chevillon F, Cabannes-Hamy A, M\u00e9chinaud F, et al. Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia. Leukemia. 2021;35:3383\u201393.","journal-title":"Leukemia"},{"key":"2929_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1048296","volume":"12","author":"Z Li","year":"2022","unstructured":"Li Z, Yang K, Song Y, Zhao Y, Wu F, Wen X, et al. CAR-T therapy followed by allogeneic hematopoietic stem cell transplantation for refractory\/relapsed acute B lymphocytic leukemia: Long-term follow-up results. Front Oncol. 2022;12:1048296.","journal-title":"Front Oncol"},{"key":"2929_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004483","volume":"10","author":"EM Holland","year":"2022","unstructured":"Holland EM, Molina JC, Dede K, Moyer D, Zhou T, Yuan CM, et al. Efficacy of second CAR-T (CART2) infusion limited by poor CART expansion and antigen modulation. J Immunother Cancer. 2022;10:e004708.","journal-title":"J Immunother Cancer"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02929-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02929-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02929-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T10:36:19Z","timestamp":1785839779000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02929-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["2929"],"URL":"https:\/\/doi.org\/10.1038\/s41409-026-02929-7","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]},"assertion":[{"value":"17 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"KL, LY, TW, and RJ are employees of Fundamenta Therapeutics, Ltd. Fundamenta Therapeutics, Ltd. provided ThisCAR-T cell products and support for cell manufacturing and quality control. These authors declare no other competing interests. The remaining authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}